Our Science
OUR PIPELINE
Through pioneering science and an unwavering commitment to patients, Alnylam has led the translation of the breakthrough discovery of RNA interference (RNAi) into an entirely new class of medicines that is disrupting disease.
RNAi therapeutics represent an innovative, clinically validated approach to gene silencing. Our multiple approved medicines, and deep pipeline of investigational therapies, are focused on addressing the needs of patients who have limited or inadequate treatment options.
Learn more about RNAi and our science ›
Learn more about current Alnylam clinical trials ›
